%0 Journal Article
%A Kerns, Sarah L
%A Amidon Morlang, Ashley
%A Lee, Sharon M
%A Peterson, Derick R
%A Marples, Brian
%A Zhang, Hong
%A Bylund, Kevin
%A Rosenzweig, Doug
%A Hall, William
%A De Ruyck, Kim
%A Rosenstein, Barry S
%A Stock, Richard G
%A Gómez-Caamaño, Antonio
%A Vega, Ana
%A Sosa-Fajardo, Paloma
%A Taboada-Valladares, Begoña
%A Aguado-Barrera, Miguel E
%A Parker, Chris
%A Veldeman, Liv
%A Fonteyne, Valérie
%A Bultijnck, Renée
%A Talbot, Christopher J
%A Paul Symonds, R.
%A Johnson, Kerstie
%A Rattay, Tim
%A Webb, Adam
%A Lambrecht, Maarten
%A de Ruysscher, Dirk
%A Vanneste, Ben
%A Choudhury, Ananya
%A Elliott, Rebecca M
%A Sperk, Elena
%A Herskind, Carsten
%A Veldwijk, Marlon R
%A Rancati, Tiziana
%A Avuzzi, Barbara
%A Valdagni, Riccardo
%A Azria, David
%A Farcy Jacquet, Marie-Pierre
%A Chang-Claude, Jenny
%A Seibold, Petra
%A West, Catharine
%A Janelsins, Michelle
%A Chen, Yuhchyau
%A Messing, Edward
%A Morrow, Gary
%A Azria, David
%A Briers, Erik
%A Chang-Claude, Jenny
%A Choudhury, Ananya
%A Dunning, Alison
%A Elliott, Rebecca M
%A Gutiérrez-Enríquez, Sara
%A Rancati, Tiziana
%A Rattay, Tim
%A Rosenstein, Barry S
%A De Ruysscher, Dirk
%A Seibold, Petra
%A Sperk, Elena
%A Paul Symonds, R.
%A Stobart, Hilary
%A Talbot, Christopher J
%A Vega, Ana
%A Veldeman, Liv
%A Ward, Tim
%A Webb, Adam
%A West, Catharine M
%T Use of Angiotensin Converting Enzyme Inhibitors is Associated with Reduced Risk of Late Bladder Toxicity Following Radiotherapy for Prostate Cancer.
%J Radiotherapy and oncology
%V 168
%@ 0167-8140
%C Amsterdam [u.a.]
%I Elsevier Science
%M DKFZ-2022-00170
%P 75-82
%D 2022
%Z Volume 168, March 2022, Pages 75-82
%X Genome-wide association studies (GWAS) of late hematuria following prostate cancer radiotherapy identified single nucleotide polymorphisms (SNPs) near AGT, encoding angiotensinogen. We tested the hypothesis that patients taking angiotensin converting enzyme inhibitors (ACEi) have a reduced risk of late hematuria. We additionally tested genetically-defined hypertension.Prostate cancer patients undergoing potentially-curative radiotherapy were enrolled onto two multi-center observational studies, URWCI (N=256) and REQUITE (N=1,437). Patients were assessed pre-radiotherapy and followed prospectively for development of toxicity for up to four years. The cumulative probability of hematuria was estimated by the Kaplan-Meier method. Multivariable grouped relative risk models assessed the effect of ACEi on time to hematuria adjusting for clinical factors and stratified by enrollment site. A polygenic risk score (PRS) for blood pressure was tested for association with hematuria in REQUITE and our Radiogenomics Consortium GWAS.Patients taking ACEi during radiotherapy had a reduced risk of hematuria (HR 0.51, 95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:35077710
%R 10.1016/j.radonc.2022.01.014
%U https://inrepo02.dkfz.de/record/178629